Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6043168 | 0.78 | KMT2A (0.47) | KDM4EMEN1KMT2APDE4BTP53 | |
| SCHEMBL12062616 | 0.78 | MEN1 (0.46) | KDM4EMEN1KMT2APDE4BMAPT | |
| SCHEMBL28135917 | 0.77 | KDM4E (0.44) | KDM4EMEN1KMT2APDE4BTP53 | |
| SCHEMBL25911400 | 0.77 | KDM4E (0.44) | KDM4EMEN1KMT2ACYP2C19ALDH1A1 | |
| SCHEMBL167812 | 0.77 | MAPT (0.56) | KDM4EMEN1KMT2APDE4BTP53 | |
| SCHEMBL31366357 | 0.75 | ALDH1A1 (0.38) | KDM4EKMT2ATP53MAPTALDH1A1 | |
| SCHEMBL2148581 | 0.75 | ALDH1A1 (0.38) | KDM4EKMT2ATP53MAPTALDH1A1 | |
| SCHEMBL3170487 | 0.75 | MEN1 (0.43) | KDM4EMEN1KMT2AMAPTTDP1 | |
| SCHEMBL16651391 | 0.75 | RIPK1 (0.34) | KDM4EMEN1KMT2APDE4B | |
| SCHEMBL5411406 | 0.74 | KDM4E (0.56) | KDM4EMEN1KMT2APDE4BCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103269592-B | Cyclic amine substituted oxazolidinone CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-11 | — | — | CN | disclosed |
| CN-103269592-A | Cyclic amine substituted oxazolidinone cetp inhibitor | MERCK SHARP & DOHME | 2013-08-28 | — | — | CN | disclosed |
| EP-1979331-B1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-8076364-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-12-13 | — | — | US | disclosed |
| US-20110092506-A1 | TRISUBSTITUTED AMINE COMPOUND | NAKAMURA YOSHINORI | 2011-04-21 | — | — | US | disclosed |
| US-7906517-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20090029994-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090023729-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| US-7452896-B2 | Pyrimidine-sulfamides and their use as endothelian receptor antagonist | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-11-18 | — | — | US | disclosed |
| US-7452896-B2 | Pyrimidine-sulfamides and their use as endothelian receptor antagonist | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-11-18 | — | — | US | disclosed |
| US-7323465-B2 | Alkansulfonamides as endothelin antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-01-29 | — | — | US | disclosed |
| WO-2007088996-A1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007088999-A1 | TRISUBSTITUTED AMINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| US-20070167472-A1 | 2-Methoxy-ethanesulfamic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-chloro-5-methoxy-phenoxy)-pyrimidin-4-yl]-amide; vasoconstrictor, mediator of cardiac, renal, endocrine functions; neurotransmitter release, activation of inflammatory cells, fibrosis, cell proliferation and differentiation | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-07-19 | — | — | US | disclosed |
| US-20070167472-A1 | 2-Methoxy-ethanesulfamic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-chloro-5-methoxy-phenoxy)-pyrimidin-4-yl]-amide; vasoconstrictor, mediator of cardiac, renal, endocrine functions; neurotransmitter release, activation of inflammatory cells, fibrosis, cell proliferation and differentiation | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-07-19 | — | — | US | disclosed |
| WO-2004050640-A1 | PYRIMIDINE-SULFAMIDES AND THEIR USE AS ENDOTHELIAN RECEPTOR ANTAGONIST | ACTELION PHARMACEUTICALS LTD (CH) | 2004-06-17 | — | — | WO | disclosed |
| US-6620932-B2 | 2-alkoxy group may be introduced into the appropriate pyrimidine derivatives at the start of the reaction | DEGUSSA AG (DE) | 2003-09-16 | — | — | US | disclosed |
| US-20030022908-A1 | 2-alkoxy-5-methoxypyrimidines or their tautomeric forms and methods for producing the same | DEGUSSA AG (DE) | 2003-01-30 | — | — | US | disclosed |
| EP-1274690-A1 | 2-ALKOXY-5-METHOXYPYRIMIDINES OR THEIR TAUTOMERIC FORMS AND METHODS FOR PRODUCING THE SAME | Degussa AG (DE) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001081320-A1 | 2-ALKOXY-5-METHOXYPYRIMIDINES OR THEIR TAUTOMERIC FORMS AND METHODS FOR PRODUCING THE SAME | DEGUSSA AG (DE) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092506-A1 | TRISUBSTITUTED AMINE COMPOUND | CETP, MTTP, APOB | KDM4E 309/4885MEN1 2509/4885KMT2A 544/4885 |
| US-20090029994-A1 | Trisubstituted amine compound | CETP, MTTP, APOB | KDM4E 309/4885MEN1 2509/4885KMT2A 544/4885 |
| US-20030022908-A1 | 2-alkoxy-5-methoxypyrimidines or their tautomeric forms and methods for producing the same | DPYD, TYMP, UMPS | KDM4E 1109/4885MEN1 1135/4885KMT2A 1253/4885 |
| US-20070167472-A1 | 2-Methoxy-ethanesulfamic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-chloro-5-methoxy-phenoxy)-pyrimidin-4-yl]-amide; vasoconstrictor, mediator of cardiac, renal, endocrine functions; neurotransmitter release, activation of inflammatory cells, fibrosis, cell proliferation and differentiation | EDNRA, EDNRB, AGTR2 | KDM4E 1272/4885MEN1 3515/4885KMT2A 2938/4885 |
| US-20090023729-A1 | Trisubstituted amine compound | CETP, MTTP, APOB | KDM4E 418/4885MEN1 2338/4885KMT2A 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.